Exenatide once weekly for the treatment of type 2 diabetes: Effectiveness and tolerability in patient subpopulations

International Journal of Clinical Practice

Volumn 66, Issue 11, 2012, Pages 1021-1032

  Pencek, R ^a   Blickensderfer, A ^a   Li, Y ^a   Brunell, S C ^a   Chen, S ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SULFONYLUREA; TRIACYLGLYCEROL;

ARTICLE; ASIAN; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CAUCASIAN; DEMOGRAPHY; DIARRHEA; DISEASE DURATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HISPANIC; HUMAN; HYPOGLYCEMIA; INJECTION SITE PRURITUS; NAUSEA; NEGRO; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; TREATMENT DURATION;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; MALE; MIDDLE AGED; NASOPHARYNGITIS; NAUSEA; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VENOMS;

EID: 84867580368     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.03006.x     Document Type: Article

References (17)

1. Tracy MA, Ward KL, Firouzabadian L, et al., Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 1999; 20: 1057-62. (Pubitemid 29229474)
2. DeYoung MB, MacConell L, Sarin V, et al., Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 2011; 13: 1145-54.
3. Amylin Phamaceuticals Incorporation. BYDUREON™ (exenatide extended-release for injectable suspension) [prescribing information]. San Diego, CA: Amylin Pharmaceuticals, Inc., 2012.
4. Shomali M, Hale P, Zdravkovic M, et al., Liraglutide, a once-daily human GLP-1 analog, improves glycemic control more than glimepiride in African American or black individuals with type 2 diabetes. Poster and Oral Presentation at the 2009 National Medical Association Annual Convention & Scientific Assembly, 25-29 July 2009, Las Vegas, NV.
5. Yang W, Chen L, Ji Q, et al., Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*). Diabetes Obes Metab 2011; 13: 81-8.
6. Gao Y, Yoon KH, Chuang LM, et al., Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. Diabetes Res Clin Pract 2009; 83: 69-76.
7. Bode BW, Brett J, Falahati A, Pratley RE,. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies. Am J Geriatr Pharmacother 2011; 9: 423-33.
8. Brunell SC, Anderson P, Pencek R, Blickendsderfer A, Li Y,. Clinical outcomes in patients with type 2 diabetes treated with exenatide twice daily or once weekly: retrospective analysis of pooled clinical data stratified by body mass index. Diabetes 2011; 60 (Suppl. 1): A283-4. Abstract 1034-P.
9. Pencek R, Pencek R, Anderson P, Brunell SC, Blickensderfer A, Li Y,. Clinical outcomes in patients with type 2 diabetes treated with exenatide twice daily or once weekly: retrospective analysis of pooled clinical data stratified by age and duration of diabetes. Diabetes 2011; 60 (Suppl. 1): A283. Abstract 1033-P. 2011.
10. Drucker D, Buse JB, Taylor K, et al., Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomized, open-label, non-inferiority study. Lancet 2008; 372: 1240-50.
11. Bergenstal RM, Wysham C, MacConell L, et al., Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431-9.
12. Diamant M, Van Gaal L, Stranks S, et al., Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-43.
13. Russell-Jones D, Cuddihy RM, Hanefeld M, et al., Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4): a 26-week, doubleblind study. Diabetes Care 2012; 35: 252-8.
14. Blevins T, Pullman J, Malloy J, et al., DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301-10.
15. Buse JB, Nauck MA, Forst T, et al., Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study. Diabetologia 2011; 54 (Suppl. 1): S38. Abstract 75.
16. Ji LN, Onishi Y, Woo AC, et al., Efficacy and safety of exenatide once weekly versus exenatide twice daily in patients of Pan-Asian descent with type 2 diabetes. World Diabetes Congress Abstract Book. 2011; P1144
17. Centers for Disease Control and Prevention. Press release: more than a third of adults estimated to have prediabetes. http://www.cdc.gov/media/ releases/2011/p0126-diabetes.html (accessed 25 July 2012).